Bullish
Vertex Pharmaceuticals (VRTX) has received FDA approval for its CASGEVY gene therapy to treat sickle cell disease and transfusion-dependent beta thala...
Neutral
Fideuram Intesa Sanpaolo Private Banking S.P.A. raised its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 11...
Vertex Pharmaceuticals announced that the FDA has approved an expanded use of CASGEVY (exagamglogene autotemcel) for patients aged 2 years and older w...
Bullish
The U.S. FDA has approved expanded use of Vertex Pharmaceuticals' gene therapy, Casgevy, for children as young as two with inherited blood disorders l...
Joy Liu filed a Form 144 proposing sales of Vertex Pharmaceuticals Inc. (VRTX) common stock, primarily attributed to restricted-stock vesting as compe...
Bullish
This article compares Dyne Therapeutics and Vertex Pharmaceuticals to determine which is a better buy in 2026. Dyne Therapeutics is a clinical-stage b...
Bearish
Carmen Bozic, Executive Vice President and Chief Medical Officer at Vertex Pharmaceuticals Inc (VRTX), sold 596 shares of the company on June 26, 2026...
Neutral
Carmen Bozic, EVP and Chief Medical Officer at Vertex Pharmaceuticals, sold 596 shares of company stock for $287,570 on June 26, 2026. This transactio...
Neutral
This article announces the filing of Form 4 for Vertex Pharmaceuticals Inc., specifically for the period ending June 30. Form 4 is a document that mus...
Vertex Pharmaceuticals (VRTX) saw a 2.32% gain despite a general market dip, outperforming the S&P 500 and the Medical sector. The drugmaker is projec...
Vertex Pharmaceuticals (VRTX) is gaining renewed attention after releasing positive Phase 3 data for its gene editing therapy, CASGEVY, in children wi...
Bullish
Vertex Pharmaceuticals Inc. (VRTX) saw its stock rise by 3.45% on June 22, driven by increased institutional investment from Rockefeller Capital Manag...
Neutral
Meadowbrook Advisors Group LLC bought a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) during the 4th quarter, accord...
Bullish
Vertex Pharmaceuticals (VRTX) is diversifying beyond its dominant cystic fibrosis franchise by developing a robust kidney disease pipeline. Key candid...
Bullish
Charles Wagner, CFO and COO of Vertex Pharmaceuticals, emphasizes the importance of a portfolio management mindset for CFOs, particularly in resource ...
Neutral
Vertex Pharmaceuticals (NASDAQ: VRTX) has filed a Form 144 notice disclosing a proposed sale of 4,062 shares of common stock on June 15, 2026. The fil...
Bullish
Vertex Pharmaceuticals recently announced positive Phase 3 data for ALYFTREK and TRIKAFTA in younger pediatric cystic fibrosis patients, reinforcing i...
Bullish
Despite "death crosses" indicating bearish technical signals for Hershey (HSY) and Vertex Pharmaceuticals (VRTX), Wall Street analysts maintain a bull...
Bullish
Vertex Pharmaceuticals (VRTX) is focused on expanding its leadership in cystic fibrosis, pain, and renal disease. The company has a robust late-stage ...
Bullish
Vertex Pharmaceuticals is strengthening its position in the cystic fibrosis market through new pediatric ALYFTREK data, TRIKAFTA regulatory progress, ...